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A B S T R A C T
Background
Cough in children is a commonly experienced symptom that is associated with increased health service utilisation and burden to
parents. The presence of chronic (equal to or more than four weeks) cough in children may indicate a serious underlying condition
such as inhaled foreign body or bronchiectasis. Codeine (and derivative)-based medications are sometimes used to treat cough due
to their antitussive properties. However, there are inherent risks associated with the use of these medications such as respiratory drive
suppression, anaesthetic-induced anaphylaxis, and addiction. Metabolic response and dosage variability place children at increased
risk of experiencing such side effects. A systematic review evaluating the quality of the available literature would be useful to inform
management practices.
Objectives
To evaluate the safety and efficacy of codeine (and derivatives) in the treatment of chronic cough in children.
Search methods
We searched the Cochrane Airways Group Register of Trials, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE
(1946 to 8 June 2016), EMBASE (1974 to 8 June 2016), the online trials registries of the World Health Organization and Clinical-
Trials.gov, and the bibliographic references of publications. We imposed no language restrictions.
Selection criteria
We considered studies eligible for analysis when: the participant population included children aged less than 18 years with chronic
cough (duration equal to or more than four weeks at the time of intervention); and the study design evaluated codeine or codeine-
based derivatives against placebo through a randomised controlled trial.
Data collection and analysis
Two review authors independently screened the search results to determine eligibility against a standardised criteria, and we had a pre-
planned method for analysis.
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Main results
We identified a total of 556 records, of which 486 records were excluded on the basis of title and abstract. We retrieved the remaining
70 references in full to determine eligibility. No studies fulfilled the inclusion criteria of this review, and thus we found no evidence to
support or oppose the use of codeine or derivatives as antitussive agents for chronic cough in children.
While chronic cough is not the same as acute cough, systematic reviews on the use of codeine efficacy for acute cough in children
conclude an overall lack of evidence to support or oppose the use of over-the-counter cough and cold medications containing codeine
(or derivatives) for treatment of acute cough in children. The lack of sufficient evidence to support the use of these medications has been
consistently reaffirmed by medical experts in international chronic cough guidelines and by governing medical and pharmaceutical
authorities in the USA, Europe, Canada, New Zealand, and Australia. Due to the lack of sufficient evidence to support efficacy, and
the known risks associated with use - in particular the increased risks for children - these medications are now not recommended for
children less than 12 years of age and children between 12 to 18 years with respiratory conditions.
Authors’ conclusions
This review has highlighted the absence of any randomised controlled trials evaluating codeine-based medications in the treatment
of childhood chronic cough. Given the potential adverse events of respiratory suppression and opioid toxicity, national therapeutic
regulatory authorities recommend the contraindication of access to codeine in children less than 12 years of age. We suggest that
clinical practice adhere to clinical practice guidelines and thus refrain from using codeine or its derivatives to treat cough in children.
Aetiological-based management practices continue to be advocated for children with chronic cough.
P L A I N L A N G U A G E S U M M A R Y
Codeine for the treatment of chronic cough in children
Review question
We sought to answer the question of whether codeine (or medications produced from codeine) are safe and effective in the treatment
of chronic cough (four weeks or longer) in children.
Background
Cough is a very commonly experienced symptom and is one of the most frequent reasons for visiting doctors and other health service
providers. The presence of chronic cough (four weeks or longer) in children may indicate a serious underlying condition. Codeine
(or medications produced from codeine) are ingredients in some non-prescription, over-the-counter cough syrups as well as some
prescribed by a doctor. These medications are used to reduce the effects of cough, although there are known risks associated with their
use, including breathing difficulties, allergic reactions, and addiction. We aimed to look at the safety and benefit of these medications
for the treatment of chronic cough in children.
Search date
We searched for any and all trials published and pending as of 8 June 2016.
Study characteristics
We searched for any randomised controlled trial comparing either codeine (or medications produced from codeine) versus placebo in
the treatment of chronic cough (4 weeks or longer) in children aged 18 years and younger.
Key results
The search identified 556 records. We reviewed and assessed all of these against predetermined inclusion/exclusion criteria. We found
no eligible studies to include in this review. However, our search did find studies that investigated codeine (or medications produced
from codeine) in the treatment of acute cough (two weeks or less) in children. Another Cochrane review specifically for children
with acute cough evaluated these studies and found no evidence to support or oppose use of codeine (or medications produced from
codeine). This overall lack of evidence is consistent with international chronic cough guidelines, which recommend treating the cause
of the cough. Due to the known risks associated with use, in particular the increased risks for children, governing bodies in the USA,
Europe, Canada, New Zealand, and Australia have stated these medications are now not recommended for children younger than 12
years of age and children between 12 to 18 years with respiratory conditions. Given the lack of supporting trials, the findings from
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trials of acute cough in children, and the known harmful side effects, we have concluded that codeine-based medications cannot be
recommended in children with chronic cough.
Quality of evidence
We found no studies and hence there is no quality of evidence.
B A C K G R O U N D
Description of the condition
Cough is a commonly experienced symptom within the com-
munity (Chang 2015), and was identified as the leading reason
for acute consultations to general practitioners in Australia be-
tween 2009 and 2010 (Britt 2010). Cough in children can be
broadly categorised into acute (coughing lasting less than two
weeks) or chronic (coughing duration longer than four weeks)
(Chang 2006a; de Jongste 2003; Gibson 2010). The latter was the
subject of this review.
Unlike acute cough (which often results from a viral infection), the
aetiology of chronic cough is diverse andmay indicate a serious un-
derlying disease such as an airway abnormality or bronchiectasis.
Irrespective of the type of cough or its aetiology, parents and carers
often seek relief for their child’s cough (Vernacchio 2008). This is
not surprising as the burden of cough is multidimensional and can
negatively impact individuals and their families (Anderson-James
2014; Marchant 2008).
Description of the intervention
Codeine is derived from the Papaver somniferum, or opium poppy
plant, and was first extracted in 1830 by a French chemist, Pierre-
Jean Robiquet (Kane 2007). Codeine is an alkaloid opiate com-
pound and is predominantly used as an analgesic and antitus-
sive (cough suppressant) agent in health care. Since the discov-
ery of codeine, numerous opiates and semi-synthetic derivatives
have been developed and utilised for many reasons, including their
antitussive properties (Kane 2007). While preparations may be
prescription controlled, many of these drugs are readily available
and easily accessible in combination therapies with antihistamines,
antipyretics, decongestants, or expectorants as over-the-counter,
non-prescription cough syrups or lozenges. The ease of accessi-
bility of such treatments has likely contributed to a perception of
their safety and efficacy and has contributed to widespread use
within the community (Lokker 2009).
How the intervention might work
Codeine (and derivatives) have been used as an antitussive for cen-
turies. The medication acts primarily through opioid receptors of
the central nervous system, although the exact mechanisms of ac-
tion are unknown (Takahama 2007). An alternative mechanism
of action is through sedation (Dickinson 2014). The pharmaco-
dynamic properties of codeine in children are poorly understood,
although there are known inherent and undesirable side effects
associated with this class of antitussives.
Side effects may include respiratory depression, pruritis, rash, fa-
cial swelling, vomiting, and ataxia (Fleming 2014). Codeine is
metabolised by several enzymes such as CYP3A4 and CYP2D6.
The latter converts codeine to morphine, the active metabolite.
There are genetic variants of CYP2D6, and rapid metabolism rates
increase the risk of respiratory drive suppression and adverse ef-
fects (Committee on Drugs 1997). Individual responsiveness to
codeine-based combination therapies is unpredictable, with age,
genetic make-up, ethnicity, and disease aetiology influencing the
outcome (Fleming 2014; Gadomski 1992).
There is growing international concern regarding the availability
and safety of codeine, with the consequences of hyper-metabolism,
drug abuse, and the risk of anaesthetic-induced anaphylaxis at the
forefront of reform agendas (European Medicines Agency 2015;
Florvaag 2012; Mattoo 1997).
Why it is important to do this review
Codeine (and derivatives)-based antitussive agents are widely used
in the paediatric population, although the mechanism of action is
poorly understood. The safety and efficacy of exposure is highly
variable, with children at increased risk of experiencing significant
adverse effects (Gadomski 1992). The burden of cough is multi-
faceted, resulting not only in parental stress and worry, but also
on a child’s ability to participate fully within society due to school
and work time loss (Marchant 2008). Rigorously evaluating the
efficacy of various treatment options, including codeine and its
derivatives as antitussive agents, will thus assist in clinical manage-
ment and allow informed burden-reduction treatment strategies
in children.
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O B J E C T I V E S
To evaluate the safety and efficacy of codeine (and derivatives) for
the treatment of chronic cough in children.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Weplanned to include randomised controlled trials (RCTs), quasi-
RCTs, and stratified RCTs that compared codeine (or derivatives)
versus placebo. We planned to include studies reported as full text,
those published as abstract only, and unpublished data.
Types of participants
Due to the differing definitions and aetiology of chronic cough
between children and adults, we sought to include studies of chil-
dren aged 18 years or younger with a diagnosis of chronic cough
(cough lasting four or more weeks).We excluded participants with
acute cough.
Types of interventions
We sought to include studies comparing medications that con-
tained codeine or codeine derivatives versus placebo.
We included the following derivative agents in the search strat-
egy: dihydrocodeine, nalodeine, azidocodeine, acetylcodeine, dex-
tromethorphan, nicocodine, pholcodine, alpha-codeimethine, 6-
succinylcodeine, 6-codeinone, 14-hydroxycodeine, n-methylco-
dinium iodine, codeine-7,8-oxide, codeine-6-glucronide, and
O(6)-codeine methyl ether.
We planned to include the following comparisons.
1. Cough mixture containing codeine or codeine derivative
only as the active ingredient versus placebo.
2. Cough mixture containing codeine or codeine derivative
plus other active ingredient/s versus cough mixture containing
placebo plus the same other active ingredient/s.
Types of outcome measures
Primary outcomes
Primary outcomes were those that reflected objective measures of
treatment superiority, non-inferiority, or inferiority, and included:
1. number of children not cured at follow-up;
2. number of children who experienced a reduction in cough
severity (clinically defined as a greater than 70% change in
severity as per previous RCTs) (Chang 1998; Marchant 2012);
3. serious adverse events (a reaction to the study drug that
results in hospital admission or loss of life, or both).
Secondary outcomes
The following secondary outcome measures contribute to the
strength of primary outcome analysis:
1. symptoms and burden of cough as reported in cough
indices such as cough quality of life scores, diary card, and cough
severity index scores;
2. adverse events/side effects (any event that is not considered
life-threatening and does not result in a hospital admission and
would otherwise not occur without exposure to the study
medication).
Reporting one or more of the outcomes listed above in the trial
was not an inclusion criterion for the review.
Search methods for identification of studies
Electronic searches
We searched the following databases.
• Cochrane Airways Group Register of Trials (via the
Cochrane Register of Studies): all years to 8 June 2016
• Cochrane Central Register of Controlled Trials
(CENTRAL) via the Cochrane Register of Studies Online: all
years to 8 June 2016
• MEDLINE (Ovid): 1946 to June week 1 2016
• EMBASE (Ovid): 1974 to week 23 2016
• Trials registries (ClinicalTrials.gov and the World Health
Organization International Clinical Trials Registry Platform
(WHO ICTRP))
The MEDLINE strategy is listed in Appendix 1. We adapted this
strategy for use in the other databases. We searched all databases
from their inception to the 8 June 2016. We searched the trials
registries of ClinicalTrials.gov and WHO ICTRP all years to 9
June 2016 (Appendix 2).Weplacedno restrictions on the language
of publication.
Searching other resources
We checked the reference lists of all relevant articles for additional
references.
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Data collection and analysis
Selection of studies
We uploaded electronic search results to the Covidence software
platform (Covidence 2015), and summarised results using the
PRISMA flow diagram (Figure 1).We identified and excluded du-
plicates and collatedmultiple reports of the same study.Two review
authors (SG, HP) independently screened the titles and abstracts
of all studies identified for inclusion. We excluded records on the
basis of the title and abstract alone when study design was clearly
defined with no ambiguity. We retrieved the full-text publications
of records that required further clarification, including those pub-
lished in a language other than English. We sought translation for
non-English publications using a standardised inclusion/exclusion
criteria sheet. Review authors independently recorded the reason
for exclusion. Where there were discrepancies, a third person (AC)
adjudicated.
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Figure 1. PRISMA study flow diagram.
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Data extraction and management
It was planned that two review authors (SG, HP) were to extract
the following study characteristics from included studies.
1. Methods: study design, total duration of study, details of
any ’run in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
However, as no studies fulfilled the inclusion criteria, data extrac-
tion was not possible.
Assessment of risk of bias in included studies
It was planned that two review authors (SG, HP) would indepen-
dently assess risk of bias for each included study using the criteria
outlined in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011). We would have resolve any disagree-
ments by discussion or by involving another review author (AC).
We planned to assess the risk of bias according to the following
domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We planned to grade each potential source of bias as high, low,
or unclear and provide a quote from the study report together
with a justification for our judgement in the ’Risk of bias’ table.
We planned to summarise the ’Risk of bias’ judgements across
different studies for each of the domains listed. Had we identi-
fied sufficient studies, we would have considered blinding sepa-
rately for different key outcomes where necessary (for example for
unblinded outcome assessment, risk of bias for all-cause mortal-
ity may be very different than for a patient-reported pain scale).
Where information on risk of bias related to unpublished data or
correspondence with a trialist, we would have noted this in the
’Risk of bias’ table.
When considering treatment effects, we planned to take into ac-
count the risk of bias for the studies that contributed to that out-
come.
Assessment of bias in conducting the systematic
review
We conducted the review according to the published protocol
and reported any deviations from it in the Differences between
protocol and review section of this systematic review.
Measures of treatment effect
We planned to analyse dichotomous data as odds ratios and con-
tinuous data as mean difference or standardised mean difference.
We planned to enter data presented as a scale with a consistent
direction of effect.
We planned to undertakemeta-analyses only where this wasmean-
ingful, that is if the treatments, participants, and underlying clin-
ical questions were similar enough for pooling to make sense.
We would have narratively described skewed data reported as me-
dians and interquartile ranges.
If multiple trial arms had been reported in a single trial, we would
have included only the relevant arms.Where two comparisons (for
example drug A versus placebo and drug B versus placebo) were
combined in the same meta-analysis, we would have halved the
control group to avoid double-counting.
Unit of analysis issues
For dichotomous data, we planned to report the proportion of
participants contributing to each outcome in comparison with
the total number randomised. For rate ratios of common events
whereby one participant may havemore than one event, we would
have used generic inverse variance. We would have taken the rate
ratios from the published papers and calculated the standard er-
rors from confidence intervals (CI) or P values published in the
papers. For cross-over studies, mean treatment differences would
have been calculated from raw data, extracted or imputed and en-
tered as fixed-effect generic inverse variance outcome, to provide
summary weighted differences and 95% CIs.
Dealing with missing data
We planned to contact investigators or study sponsors in order to
verify key study characteristics and obtain missing numerical out-
come data where possible (for example when a study was identified
as abstract only).Where this was not possible, and themissing data
were thought to introduce serious bias, we would have explored
the impact of including such studies in the overall assessment of
results by a sensitivity analysis.
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Assessment of heterogeneity
We planned to describe and test any heterogeneity between the
study results to see if it reached statistical significance using a Chi
2 test. We would have included the 95% CI estimated using a
random-effects model whenever there were concerns about statis-
tical heterogeneity. We would have considered heterogeneity sig-
nificant when the P value was less than 0.10 (Higgins 2011). We
would have used the I2 statistic to measure heterogeneity among
the trials in each analysis. Had we identified substantial hetero-
geneity, we would have reported this and explored possible causes
by prespecified subgroup analysis.
Assessment of reporting biases
Had we been able to pool more than 10 trials, we would have
created and examined a funnel plot to explore possible small-study
and publication biases and would have consulted a statistician to
ensure appropriate analysis was conducted.
Data synthesis
We planned to use a random-effects model and perform a sensi-
tivity analysis with a fixed-effect model.
’Summary of findings’ table
We planned to create a ’Summary of findings’ table reporting the
following outcomes: number of children not cured at follow-up;
number of children who experienced a reduction in cough sever-
ity; serious adverse events; and symptoms and burden of cough
as reported in cough indices tools. We planned to use the five
GRADE considerations (study limitations, consistency of effect,
imprecision, indirectness, and publication bias) to assess the qual-
ity of a body of evidence as it relates to the studies that con-
tribute data to the meta-analyses for the prespecified outcomes.
We planned to use methods and recommendations described in
Section 8.5 and Chapter 12 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011), using GRADEpro
software (GRADEpro GDT). We planned to justify all decisions
to down- or up-grade the quality of studies using footnotes and
make comments to aid the reader’s understanding of the review
where necessary.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses.
1. Children aged less than seven years and seven years or older.
2. Children with diagnosed respiratory conditions (e.g. cystic
fibrosis (CF), non-CF bronchiectasis) versus children with no
diagnosed respiratory condition.
3. Active ingredient other than codeine (e.g. expectorants,
antihistamines, decongestants, antipyretics, substances that may
soften coughing such as honey or syrup).
We planned to use the following outcomes in subgroup analyses.
1. Number of children not cured at follow-up.
2. Number of children who experienced a reduction in cough
severity based on objective symptom measures of sputum
production, runny nose, fevers, and air entry; as well as
subjective measures of cough burden.
3. Serious adverse events.
We planned to use the formal test for subgroup interactions in
Review Manager 5 (RevMan 2014).
Sensitivity analysis
We planned to carry out the following sensitivity analyses.
1. A comparison based on ’Risk of bias’ assessments.
2. A comparison of available-case analyses versus true
intention-to-treat (ITT) analyses, when the ITT analyses were
imputed with best-case and worse-case outcome data.
3. A comparison of results from fixed-effect models versus
results from random-effects models.
R E S U L T S
Description of studies
We identified 903 records through database searching and an ad-
ditional 25 records through other sources. After removing dupli-
cates, we screened 556 records and excluded 486 records. We re-
trieved full-text articles for the remaining 70 records, of which 23
were excluded due to irrelevance and 47 were excluded with rea-
sons. We found no studies that were eligible for inclusion in this
review. See Figure 1 for PRISMA diagram and the Characteristics
of excluded studies table for specific details on excluded records.
Results of the search
We initially performed the Cochrane Airways Group Register of
Trials literature search on 27March 2015, and subsequently re-ran
the search on the 11 September 2015 and then again on the 8 June
2016, which yielded a total of 903 references (Figure 1). A search
of ClinicalTrials.gov and the WHO ICTRP yielded an additional
25 results. After de-duplication, we considered 556 abstracts for
inclusion against the predetermined criteria.
We excluded a total of 486 studies on the basis of the abstract alone.
We retrieved full-text publications for the remaining 70 references
in order to further determine inclusion eligibility. Of these, 16
articles were published in a language other than English (German,
Italian, Czech, Spanish, and French). Translation was provided
against a standardised inclusion/exclusion template.We deemed a
total of 23 records irrelevant. The remaining 47 publications did
not fulfil the inclusion criteria; reasons for exclusion are provided
in the Characteristics of excluded studies table.
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Included studies
There were no included studies.
Excluded studies
Reasons for exclusion of the aforementioned full-text articles were
either solely, or a combination of, the following: non-RCT publi-
cation (n = 15); non-placebo-controlled study design (n = 6); stud-
ies evaluating acute cough (n = 6); and studies with an adult-only
participant population (n = 20). We excluded NCT02651116 be-
cause it did not fit our inclusion criteria (acute cough), however
this study is ongoing. We have provided full details of reasons for
exclusion in the Characteristics of excluded studies table.
Risk of bias in included studies
No studies met the inclusion criteria.
Effects of interventions
Due to a lack of included studies, we were unable to evaluate
the effects of codeine (and derivatives)-based medications for the
treatment of chronic cough in children.
D I S C U S S I O N
Summary of main results
We identified no studies eligible for inclusion in this review, and
thus found no evidence to support or oppose the use of codeine or
derivatives as antitussive agents for chronic cough in children. Our
review process identified paediatric studies that evaluated acute
cough, in Bhattacharya 2013, Paul 2004, Shadkam 2010, Taylor
1993, and Yoder 2006, and adult-specific chronic cough trials
(Barroso 1973; Dierckx 1981; Edwards 1977; Matthys 1983,
Matthys 1985; Thackray 1978).
Of the paediatric-specific RCTs that evaluated acute cough
(Bhattacharya 2013; Paul 2004; Shadkam 2010; Taylor 1993;
Yoder 2006), none reported any statistically significant difference
in cough severity between treatment arm and placebo. As the eval-
uation of safety was an objective of this review, and the authors re-
ported side effects, we have provided a summary of these findings
below.
A single-dose, double-blind, placebo-controlled RCT evaluated
dextromethorphan, diphenhydramine (an antihistamine) against
placebo for the treatment of nocturnal cough due to upper res-
piratory tract infections in 37 children aged 6 to 18 years (Yoder
2006). The mean cough duration of each treatment arm was 4.17,
3.92, and 4.23 days, respectively. This study found no difference
between treatment arms and reported no adverse effects. A simi-
lar single-dose RCT of dextromethorphan, diphenhydramine, and
placebo on acute (seven days or less) nocturnal cough in children
found that neither drugwas superior to placebo in regards to reduc-
ing the frequency, severity, and bothersome nature of cough (Paul
2004). More notably, however, this study did report an increased
adverse reaction of insomnia in the dextromethorphan arm, but
this was not significant (P = 0.07). The design of this study was
limited by the inclusion of concurrent antibiotic treatments, com-
mon analgesics such as acetaminophen and ibuprofen, adminis-
tration of a single dose, and the possibility of placebo effect. These
findings are consistent with an earlier study by Taylor 1993, who
conducted an RCT of 49 children with acute cough (duration of
less than 12 days) and found that codeine or dextromethorphan
compared to placebo was not more efficacious in reducing cough
score and symptom score.
Bhattacharya 2013 conducted a double-blind RCT of dex-
tromethorphan, promethazine, and placebo in 120 children with
acute cough. The study found that when compared to placebo the
treatment arms did not confer any greater benefit with respect to
symptom scores. The authors also noted that in the entire cohort
there was a propensity for the cough to resolve, irrespective of
the intervention type (Bhattacharya 2013). The cohort was evenly
divided between groups, with 40 children in each arm. Adverse
events were higher in children treated with dextromethorphan
(32.5%) compared to the placebo group (5%). Adverse events in-
cluded abdominal pain, nausea, vomiting, drowsiness, and irri-
tability.
In a non-blind RCT between dextromethorphan, diphenhy-
dramine, honey, and a control group involving 139 children (mean
age 37.75 months) with acute cough of 5 days, Shadkam 2010
found honey to be more effective in improving cough frequency,
cough severity, and sleep quality when comparing honey with each
group separately. However, after each intervention (that is honey,
dextromethorphan, and diphenhydramine), the mean difference
from baseline was statistically significant. No side effects were re-
ported in the dextromethorphan arm, and in spite of the relative
superiority of honey, nervousness was a reported adverse reaction
in two children, and the authors further acknowledged the risk
associated with honey with regards to botulism in children aged
less than 1 year.
The evidence pertaining to acute-cough management practices
was previously evaluated by Smith 2014, who conducted a system-
atic review of evidence evaluating the antitussive efficacy of over-
the-counter (OTC) medications in the treatment of acute cough
in both adults and children. This review similarly found an overall
lack of well-designed studies and no evidence for or against the
efficacy of OTC antitussive medications. The lack of evidence to
support codeine and OTC medications for cough in children is
further reflected in their absence from expert position statements
and international cough guidelines (Berlin 1997; Chang 2006b;
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Gibson 2010; Gibson 2016; Shields 2008).
An increased awareness of risks associated with codeine has
prompted many governmental bodies to review legislation and
moderate availability of these drugs, and in recent years there has
been an increasing international trend toward greater regulatory
framework surrounding the availability and use of codeine in chil-
dren. Following the AmericanCollege of Chest Physician’s chronic
cough guidelines, which recommended against using codeine and
OTC medications for cough in children (Chang 2006b), and a
citizen petition on the safety and efficacy of OTC cough and cold
medications, the US Food and Drug Administration convened
an expert advisory committee to evaluate the dispensing practices
and accessibility of OTC medications to children (US Food and
Drug Administration 2015). More recently, in April 2015 the
Pharmacovigilance Risk Assessment Committee (PRAC) of the
European Medicines Agency conducted an investigation into the
use of codeine-based medications as antitussive agents. The in-
vestigation concluded that there is a lack of sufficient evidence to
support the use of codeine as an effective antitussive agent and that
there are continued and varied safety concerns associated with this
drug. As a result, the PRAC found codeine to be contraindicated
in children less than 12 years of age and recommended it not be
used. The report further recommended such medications not be
used by children aged 12 to 18 years with breathing difficulties;
any person known to be an ultra-rapid metaboliser; or breastfeed-
ing mothers (European Medicines Agency 2015). Principal jus-
tification for reform is the unpredictability of codeine to mor-
phine conversion in children and the increased vulnerabilities of
children predisposed to airway insufficiency (EuropeanMedicines
Agency 2015). Similar conclusions pertaining to codeine use were
made following investigations by Health Canada (Health Canada
2015), theNewZealandMedicines Adverse Reactions Committee
(Medsafe 2015), and the Therapeutic Goods Association of Aus-
tralia (Therapeutic Goods Administration 2015). Reviews into the
continued risks, drug availability, and scheduling classifications
are currently under way in the United States, US Food and Drug
Administration 2016, and in Australia, where these medications
continue to be made available OTC for children aged 6 to 11
years.
Overall completeness and applicability of
evidence
This review has highlighted a considerable gap in evidence eval-
uating codeine (and derivatives) antitussive agents in childhood
chronic cough. Identified studies of relevance focused onpaediatric
populations with acute cough or on adult populations. The patho-
physiological differences between adults and children, in addition
to the different aetiologies between acute and chronic cough, limit
the overall generalisability of these findings.
Quality of the evidence
We found no evidence to support or oppose the use of codeine (or
derivatives) for the management of chronic cough in children.
Potential biases in the review process
There were no protocol deviations within this review process, and
two review authors independently reviewed the searches using
a standardised inclusion/exclusion criteria. We thus believe that
there were no potential biases in the determination of studies eli-
gible for inclusion in this review.
Agreements and disagreements with other
studies or reviews
Our findings of the absence of any RCTs on the efficacy of codeine
and its derivatives for chronic cough, along with its potential seri-
ous adverse events including death, are consistent with other prior
systematic reviews undertaken in the writing of national and in-
ternational cough guidelines for children (Chang 2006b; Gibson
2010; Shields 2008). In acute cough, a systematic review found
“codeine to be nomore effective than placebo” (Smith 2014). This
Cochrane review on OTC medications for children and adults
concluded that “there is no good evidence for or against the ef-
fectiveness of over-the-counter cough medicine” (Smith 2014). In
adults with chronic cough, a systematic review found codeine and
dextromethorphan more beneficial in reducing cough frequency
and severity than placebo but, due to a limited number of studies
and study design flaws, the authors concluded that “there were
insufficient data to draw conclusions about their relative efficacy”
(Yancy 2013).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is currently no published RCT and hence no evidence
on the efficacy of codeine (or codeine derivatives)-based medica-
tions as antitussives in improving clinical outcomes for chronic
cough in children. There are, however, documented risks associ-
ated with the use of these medications, and children are particu-
larly at risk. There is a high degree of variability in codeine-mor-
phine metabolism in children, with the potential adverse events
of respiratory suppression and opioid-toxicity being particularly
concerning. Furthermore, in the management of chronic cough in
children, the underlying aetiology should be defined, rather than
the cough empirically treated, as recommended in national cough
guidelines and systematic reviews (Chang 2006b; Chang 2016;
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Gibson 2010; Shields 2008). Thus, as recommended in many na-
tional guidelines, it is currently advocated that codeine and its
derivatives are not used for cough in children less than 12 years of
age.
Implications for research
Childhood chronic cough is a substantial burden for families and
the healthcare system alike. This review has highlighted a lack of
high-quality RCTs evaluating codeine-based medications in the
treatment of childhood chronic cough. However, given the asso-
ciated risks in children and that aetiological-based management
practices are advocated in the management of chronic cough in
children (Chang 2006b; Chang 2016), it is highly unlikely that
RCTs using currently available preparations of codeine or/and its
derivatives will be undertaken in children. If future derivatives that
do not have the side effects associated with codeine (and deriva-
tives) become available, such studies should be parallel, double-
blinded RCTs using validated cough outcome measures that in-
clude patient-relevant and objective outcomes (Boulet 2015),
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aliprandi 2004 Excluded as non-placebo controlled. Study design compared levodropizine, codeine, and DL-cloperastine
against levocloperastine without a placebo arm
Arroll 2005 Non-RCT (literature review)
Barroso 1973 Excluded as wrong population (adult). RCT of PB-89, codeine phospate, and placebo in adults with pul-
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Berlin 1997 Non-RCT. Expert panel evidence review and recommendation
Bhattacharya 2013 Acute cough study. RCT of promethazine, dextromethorphan, and placebo in children
Blanchard 2013 Non-RCT (literature review)
Bolser 2006 Non-RCT (literature review)
Bolser 2006a Non-RCT (literature review)
Bolser 2007 Non-RCT (literature review)
Chang 2006 Non-RCT. Expert panel evidence review and recommendation
Chang 2014 Excluded as non-RCT (systematic review of acute cough related to pneumonia)
Chicouri 1985 Excluded as study was on acute cough in adults
Dierckx 1981 Excluded as study was in adults. Double-blind RCT of glaucine, codeine, and placebo in adults with chronic
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Eddy 1969 Non-RCT (literature review)
Edwards 1977 Excluded as study was on an adult population. Double-blind RCT of pholcodine compound versus resinated
and unresinated pholcodine versus placebo versus control
Gruber 2000 Non-RCT (literature review)
Kleibel 1980 Excluded as wrong population (adult)
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Kleibel 1981 Excluded as study was on adults
Koster 1970 Excluded as study was on adults
Loos 1973 Excluded as study was on adults
Lucchesi 1971 Excluded as study was on adults
Matera 1977 Excluded as study was on adults
Matthys 1983 Excluded as study was on adults. RCT evaluating dextromethorphan hydrobromide, codeine phospate, and
placebo in adults with chronic cough
Matthys 1985 Excluded as study was on adults. RCT evaluating noscapine, dextromethorphan, dihydrocodeine, and
placebo for the treatment of chronic cough in adults
Matts 1977 Excluded as study was on adults. Non-placebo-controlled RCT evaluating 2 combination therapies, dex-
tromethorphan/guaifenesin (Lotussin) and linctus diphenhydramine, for the treatment of chronic cough in
adults
Maulik 2001 Non-RCT (literature review)
Mizoguchi 2007 Excluded as acute cough in adults
NCT02651116 Excluded as study was on acute cough in children. RCT evaluating dextromethorphan hydrobromide and
placebo. Study is ongoing and still in recruitment phase
Oduwole 2010 Non-RCT. Systematic review evaluating honey for acute cough in children
Palumbo-Vargas 1971 Excluded as non-placebo-controlled trial; single-arm study using dihydrocodeine thiocyanate/pentetrazol
(Cardiazol-Paracodina)
Paul 2004 Excluded as studywas on acute cough in children≤ 7years. RCTevaluated diphenhydromine, dextromethor-
phan, and placebo
Rose 1967 Excluded as non-placebo-controlled, adult population-based RCT
Ruan 1997 Excluded as study was on adults
Schlesinger 1994 Excluded as non-placebo-controlled study
Segal 1978 Non-RCT. Expert panel evidence review and recommendation
Sevelius 1966 Excluded as study was on adults
Sevelius 1971 Excluded as study was on adults
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Shadkam 2010 Excluded as study was on acute cough in children. Non-placebo-controlled RCT evaluated honey, diphen-
hydromine, and dextromethorphan against a control group receiving supportive therapies only. Supportive
therapies were offered to all arms and included saline nose drops, water vapor, cleaning a blocked nose, and
using acetaminophen if fever was present
Skoner 2005 Non-RCT (commentary)
Smith 2014 Non-RCT (systematic review)
Thackray 1978 Excluded as study was on adults
Vornov 2014 Excluded as study was on adults
Wilhelmi 1977 Excluded as non-placebo-controlled study
Yoder 2006 Excluded as study was on acute cough
Zanasi 1993 Excluded as wrong study design. RCT evaluating dextromethorphan and guaifenesin against a placebo
control arm with a participant age range of 40 to 72 years. The study did include a small paediatric treatment
group but not a paediatric placebo-controlled cohort as comparator
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Database search strategies
MEDLINE (Ovid)
1. Cough/
2. exp Bronchitis/
3. (cough$ or bronchit$).tw.
4. or/1-3
5. exp Codeine/
6. codeine$.tw.
7. N-methylcodinium$.tw.
8. nordihydrocodeine$.tw.
9. alpha-codeimethine$.tw.
10. dihydrocodeine$.tw.
11. 6-succinylcodeine$.tw.
12. acetylcodeine$.tw.
13. 14-hydroxycodeine$.tw.
14. 6-codeinone$.tw.
15. pholcodine.tw.
16. nicocodine.tw.
17. dihydrocodeine.tw.
18. nalodeine.tw.
19. azidocodeine.tw.
20. dextromethorphan.tw.
21. or/5-20
22. 4 and 21
23. (controlled clinical trial or randomized controlled trial).pt.
24. (randomized or randomised).ab,ti.
25. placebo.ab,ti.
26. dt.fs.
27. randomly.ab,ti.
28. trial.ab,ti.
29. groups.ab,ti.
30. or/23-29
31. Animals/
32. Humans/
33. 31 not (31 and 32)
34. 30 not 33
35. 22 and 34
EMBASE (Ovid)
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1. exp coughing/
2. exp bronchitis/
3. (cough$ or bronchit$).tw.
4. or/1-3
5. exp codeine/
6. codeine$.tw.
7. N-methylcodinium$.tw.
8. nordihydrocodeine$.tw.
9. alpha-codeimethine$.tw.
10. dihydrocodeine$.tw.
11. 6-succinylcodeine$.tw.
12. acetylcodeine$.tw.
13. 14-hydroxycodeine$.tw.
14. 6-codeinone$.tw.
15. pholcodine.tw.
16. nicocodine.tw.
17. dihydrocodeine.tw.
18. nalodeine.tw.
19. azidocodeine.tw.
20. dextromethorphan.tw.
21. or/5-20
22. 4 and 21
23. Randomized Controlled Trial/
24. randomization/
25. controlled clinical trial/
26. Double Blind Procedure/
27. Single Blind Procedure/
28. Crossover Procedure/
29. (clinica$ adj3 trial$).tw.
30. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (mask$ or blind$ or method$)).tw.
31. exp Placebo/
32. placebo$.ti,ab.
33. random$.ti,ab.
34. ((control$ or prospectiv$) adj3 (trial$ or method$ or stud$)).tw.
35. (crossover$ or cross-over$).ti,ab.
36. or/23-35
37. exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
38. human/ or normal human/ or human cell/
39. 37 and 38
40. 37 not 39
41. 36 not 40
42. 22 and 41
CENTRAL (CRS Online)
#1 MeSH DESCRIPTOR Cough
#2 MeSH DESCRIPTOR Bronchitis Explode All
#3 cough* or bronchitis*
#4 #1 OR #2 OR #3
#5 MeSH DESCRIPTOR Codeine Explode All
#6 codeine*
#7 N-methylcodinium*
#8 nordihydrocodeine*
20Codeine versus placebo for chronic cough in children (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
#9 alpha-codeimethine*
#10 dihydrocodeine*
#11 6-succinylcodeine*
#12 acetylcodeine
#13 14-hydroxycodeine
#14 6-codeinone*
#15 pholcodine
#16 nicocodine
#17 dihydrocodeine
#18 nalodeine
#19 azidocodeine
#20 dextromethorphan
#21 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20
#22 #4 and #21
#23 (#22) AND (INREGISTER)
Appendix 2. Search terms for ClinicalTrials.gov and WHO ICTRP
Condition
1. cough
Intervention
1. codeine
2. N-methylcodinium
3. nordihydrocodeine
4. alpha-codeimethine
5. dihydrocodeine
6. 6-succinylcodeine
7. acetylcodeine
8. 14-hydroxycodeine
9. 6-codeinone
10. pholcodine
11. nicocodine
12. dihydrocodeine
13. nalodeine
14. azidocodeine
15. dextromethorphan
16. codeine-7,8-oxide,
17. codeine-6-glucronide
18. O(6)-codeine methyl ether.
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C O N T R I B U T I O N S O F A U T H O R S
SG and HP assessed all search results for eligibility, and AC adjudicated on disagreements. SG was the predominant contributor to the
abstract, plain language summary, background, results, discussion, authors’ conclusions, and ’Characteristics of excluded studies’ table.
HP was the predominant contributor to the data analysis strategy, and both HP and SG contributed to the body of methodology. AC
provided guidance with protocol development. HP, AC, and JM edited the review.
All review authors approved the final draft before submission.
D E C L A R A T I O N S O F I N T E R E S T
AC is the recipient of a grant from GlaxoSmithKline to study the effect of a vaccine on the bacteria in bronchoalvoelar lavage of
children, a topic unrelated to this review. AC is an author of articles referenced within the background of this protocol.
SG, JM and HP: none known
S O U R C E S O F S U P P O R T
Internal sources
• The authors declare that no such funding was received for this systematic review, Other.
External sources
• National Health and Medical Research Council (NHMRC), Australia.
AC is supported by a NHMRC Practitioner Fellowship (grant 1058213) and HP is supported through a NHMRC Centre for
Research Excellence in Indigenous Lung Health (grant 1040830) post doc fellowship
• Lung Foundation of Australia/Australian Satellite of the Cochrane Airways Group Scholarship to SG, Australia.
Scholarship funds facilitated author attendance at a Cochrane review workshop and contributed towards conference attendance where
the review findings were presented.
• Queensland University of Technology, Other.
SG and HP are employees of the Queensland University of Technology. SG is the recipient of an Australian Postgraduate Award and
QUT Excellence Top-Up Scholarship awarded by AC.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
There were no protocol deviations, however a co-author, Julie Marchant, was added to the review.
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